secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibitor Therapeutics, Inc. (INTI)
CIK:        0001042418
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001193125-23-294696
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibitor Therapeutics signs exclusive worldwide license with JHU for itraconazole in three cancers
--------------------------------------------------------------------------------

- Exclusive worldwide license to U.S. Patent 8,980,930 covering itraconazole as an angiogenesis inhibitor.
- Licensed field of use: prostate cancer, basal cell carcinoma (including BCC nevus syndrome), and lung cancer.
- Financial terms include upfront fee, minimum annual royalties, milestone payments, and royalties on net sales.
- Company cites this as a critical milestone toward commercializing itraconazole in multiple oncology indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1042418/000119312523294696/0001193125-23-294696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1042418/000119312523294696/d502337d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-294696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer